Famciclovir 250mg Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Take 250 mg of famciclovir orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Take 250 mg of this medicine orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of an acute recurrent episode of genital herpes Adults: Take 125 mg of this medicine orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Take 250 mg of this medicine orally twice daily. Periodically discontinue treatment every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Because creatinine clearance of this medicine is reduced in patients with renal impairment, adjust the dose with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose twice daily 10～29 250 mg per dose once daily 2) Treatment of an acute recurrent episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 125 mg per dose twice daily 10～29 125 mg per dose once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose twice daily 10～29 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, it is preferable to administer the medicine every 48 hours, taking the dialysis interval into consideration. Hemodialysis for 4 hours reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This medication should not be used in patients who have had an allergic reaction to this medication or its active ingredient. Additionally, patients with genetic lactose intolerance or specific lactose metabolism disorders should not take this medication due to the lactose it contains. Patients with impaired kidney function need to exercise caution when using this medication, and dose adjustment may be necessary. During treatment with this medication, symptoms such as headaches, dizziness, nausea, vomiting, abdominal pain, and diarrhea may occur, and if symptoms are severe, patients should consult a physician. Skin rashes or itching may occur, and in rare severe cases, serious skin reactions may develop, so any unusual symptoms should be reported to healthcare personnel immediately. This medication does not cure genital herpes, so it is important to avoid sexual contact and maintain safe sexual practices during treatment. Caution should be exercised when driving or operating machinery if dizziness or drowsiness is experienced. Patients with slightly impaired liver function do not require special dose adjustments; however, those with severe liver impairment should use it cautiously, as efficacy may be reduced. This medication may interact with other drugs, so patients should inform their healthcare provider of any other medications they are taking. Women who are pregnant or may become pregnant should carefully weigh the benefits and risks of using this medication and should consult with a healthcare professional if breastfeeding. It is generally advisable not to use this medication in children under 18 years of age, as safety and efficacy have not been established. Elderly patients generally do not require dose adjustments; however, dosage should be adjusted in cases of decreased kidney function. In the case of overdose, appropriate medical treatment is required, and the concentration of the active ingredient can be reduced through dialysis. This medication should be stored in a dry place at or below 30 degrees Celsius and kept out of reach of children. Additionally, transferring to another container from the original package should be avoided to maintain quality and safety.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also recommended to store it in a cool, dry place at or below 30 degrees Celsius.

Appearance

White circular film-coated tablet

Package unit

21 tablets (7 tablets/PTP x 3)